MedPath

SIHUAN PHARM

SIHUAN PHARM logo
🇨🇳China
Ownership
Public
Established
2010-10-06
Employees
2.6K
Market Cap
-
Website
http://www.sihuanpharm.com
Introduction

Sihuan Pharmaceutical Holding Group Co., Ltd. (“Sihuan Pharmaceutical” or the “Company”, together with its subsidiaries is the “Group”) (stock code: 00460.HK) was founded in 2001 and listed on the main board of the Hong Kong Stock Exchange Limited in 2010. It is an international medical, aesthetic and biopharmaceutical enterprise with an independent and leading independent production, research and development (“R&D”) technology platform led by innovation and a mature and excellent sales system. Sihuan Pharmaceutical focuses on high-growth treatment fields such as medical aesthetics, oncology, metabolism, diabetes, cardiovascular, modern traditional Chinese medicine, and industrial marijuana, and has always adhered to the overall strategic goal of “adhering to the full speed promotion of Sihuan Medical Aesthetics and Biopharmaceuticals two-wheel drive strategy” to build a leading medical, aesthetic and biopharmaceutical enterprise in China.

A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Advanced Solid Tumors
Interventions
First Posted Date
2015-05-13
Last Posted Date
2022-03-04
Lead Sponsor
Sihuan Pharmaceutical Holdings Group Ltd.
Target Recruit Count
35
Registration Number
NCT02442414
Locations
🇺🇸

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States

🇺🇸

University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States

🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

A Clinical Trial To Evaluate Efficacy And Safety Of Levophencynonate Hydrochloride In Patient With Vertigo

Phase 2
Completed
Conditions
Vertigo
Interventions
First Posted Date
2014-11-24
Last Posted Date
2016-04-15
Lead Sponsor
Sihuan Pharmaceutical Holdings Group Ltd.
Target Recruit Count
98
Registration Number
NCT02299804
Locations
🇨🇳

Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China

Levo Phencynonate Hydrochloride for the Prevention of Seasickness

Phase 2
Completed
Conditions
Motion Sickness
Interventions
Drug: placebo
Drug: levo phencynonate hydrochloride
First Posted Date
2014-09-16
Last Posted Date
2015-05-07
Lead Sponsor
Sihuan Pharmaceutical Holdings Group Ltd.
Target Recruit Count
180
Registration Number
NCT02241629
Locations
🇨🇳

Qingdao municipal hospital, Qingdao, Shandong, China

© Copyright 2025. All Rights Reserved by MedPath